Janssen China Launches '2023 Deep Horizon Initiative' to Advance Healthy China with Multi-Party Collaborations

On December 27, 2022, Janssen China successfully held the launch ceremony of the "2023 Janssen China Deep Realm Plan" and a series of strategic cooperation project signings. Numerous industry experts, societies, associations, partners, and media were invited to witness this milestone moment. Guided by the strategic principle of “putting people's health at the center,” and to explore and address more unmet patient needs, Janssen China officially launched the "2023 Janssen China Deep Realm Plan." On the same day, Janssen China reached strategic cooperation agreements with the China Primary Health Care Foundation, the Chinese Society for Cell Biology, and the Chinese Anti-Tuberculosis Association, aiming to jointly promote discipline development, scientific research innovation, and the improvement of diagnostic and treatment standards in key disease areas, and to collectively advance the construction of Healthy China.
"2023 Deep Realm Plan": Driving Rapid Development with Three "Deep" Engines

In recent years, with the implementation of the "Healthy China" strategic guidelines and the guidance of national policies encouraging innovation, China's healthcare industry has entered a phase of rapid development. At the same time, patients' medical needs in the field of major diseases, as well as their demand for high-quality healthy living, are also increasing. As one of the earliest multinational pharmaceutical companies to enter China, over the past 37 years, Janssen China has been committed to driving transformative medical innovations, focusing on China’s healthcare needs, and continuously researching, introducing, and producing high-quality medicines and innovative health solutions. In response to the "Healthy China 2030" blueprint and to better meet the growing health demands of patients, Janssen China officially launched the "Janssen China Deep Realm Plan 2023."

(Speech by Ms. Zheng Lei, President of Janssen China, at the event)
Ms. Zheng Lei, President of Janssen China, stated at the launch ceremony, "The 2023 Janssen China Deep Realm Plan will continue to adhere to the three core strategies of science-based, mission-driven, and patient-first, using the three 'deep' engines to accelerate progress in academic disciplines, industry development, and further improvement of patient services. Transformative medical innovation is the core driving force behind the development of the healthcare industry. Therefore, Janssen will continue to deepen its value of 'science-based', increase investment in scientific research innovation and expand cooperation to promote 'new depth' in scientific research innovation. At the same time, Janssen will continue to leverage its deep roots in China's development, adhering to the principle of 'mission-driven', with a belief in 'going far and deep', fulfilling its commitment to serve China, and contributing to the high-quality development of China's healthcare industry. Our efforts also uphold the concept of 'patient-first', satisfying patients' needs on a 'deeper level', helping patients return to healthy lives, accelerating the creation of a future without disease, so that patients no longer have to wait."

("2023 Xian Janssen Deep Realm Plan in China")
Joining Hands with Multiple Parties to Build a Transformative Healthcare Innovation Ecosystem
Transformative healthcare innovation is an endless scientific exploration, and the needs of patients for disease management are an unending life subject, akin to a boundless universe filled with unknown territories waiting to be explored and conquered. At the launch ceremony of the "2023 Deep Realm Initiative," representatives from Janssen China and attending guests engaged in a vibrant exchange of ideas on the theme of "Exploring the 'Depth' and 'Breadth' of Patient Services against the backdrop of Healthy China." After discussion, the attendees reached a consensus: the improvement and enhancement of patient services require the joint efforts of all stakeholders and professionals in the healthcare field. During the event, Janssen China announced strategic partnerships with the China Primary Health Care Foundation, the Chinese Society for Cell Biology, and the Chinese Anti-Tuberculosis Association. This series of strategic cooperation agreements marks the first step in "Janssen China’s 2023 Deep Realm Initiative." Through close collaboration between industry, academia, and research, the partnerships will leverage the resource advantages of both parties to promote collaborative innovation, build a healthcare innovation ecosystem, support clinical research capacity building and standardized diagnosis and treatment in key disease areas, and jointly advance the construction of Healthy China, ultimately benefiting a wide range of patients across China.

"Multi-Department Clinical Doctor Research Capability Enhancement Training Camp" Project

In response to the national call for the "Action Plan for High-Quality Development of Public Hospitals (2021-2025)," to promote the development of clinical research disciplines, enhance the clinical research capabilities of Chinese healthcare workers, support the sustainable development of hospitals, and cultivate more medical scientists for China's pharmaceutical science and technology innovation, Janssen China has partnered with the China Primary Health Care Foundation to launch the "Multi-Department Clinical Doctor Research Capability Enhancement Training Camp" project. This project will focus on multiple disease areas such as solid tumors like lung cancer and bladder cancer, neuropsychiatric fields like schizophrenia, as well as myeloma, lymphoma, dermatology, and inflammatory bowel disease. It aims to improve doctors' clinical research abilities, achieve high synergy between clinical research and clinical practice, enhance the standardization of disease diagnosis and treatment, and empower the sustainable development of hospitals. To ensure the high-quality advancement and completion of the project, an external expert advisory committee has been established, appointing Professor Siyan Zhan, Deputy Director of the Peking University Center for Evidence-Based Medicine and recipient of the "Wu Yang Award," as the chairperson.

Mr. Zhou Qingnian, Deputy Chairman and Secretary-General of the China Primary Health Care Foundation, stated, "Exploring the depth and breadth of patient services" requires enhancing the capacity building of personnel in relevant fields as a key focus. Therefore, our strategic cooperation with Janssen China aims to start by improving the research capabilities of clinical doctors from multiple departments, enhancing clinical medical research capabilities, and promoting the standardization of disease diagnosis and treatment processes, thereby providing better services to a wider patient population.

"Lymphoma Field Strategic Cooperation Plan" Project

The advancement of healthcare requires the joint efforts of clinical experts and basic research scholars, with medical research progress and improvement in disease diagnosis and treatment needing to develop synergistically and reinforce each other. To strengthen the mutually reinforcing effect of medical research and clinical capabilities across different disease areas, Janssen China has partnered with the Chinese Society for Cell Biology to launch the "Strategic Cooperation Plan in Lymphoma". This project will focus on lymphoma, engaging in in-depth cooperation in areas such as capacity building for professionals in the lymphoma field and fostering communication and collaboration between fundamental science and lymphoma medical care. The initiative aims to promote the exchange of research findings and explore future directions within the lymphoma field, contributing to the development of a technology-driven powerful nation and advancing the healthcare industry in China.

Professor Chaojun Li, Vice Chairman of the Chinese Society for Cell Biology, stated: Science and technology are the primary productive forces, talent is the first resource, and innovation is the primary driving force. The society has been committed to actively playing the role of a pivotal platform and leveraging the resource advantages of expert think tanks, deepening cooperation with enterprises, and exploring diversified collaboration models between academic institutions and enterprises to fully stimulate the vitality of scientific and technological innovation, serving the high-quality development of a science and technology powerhouse. We also hope that through this strategic cooperation focusing on hematological oncology, we can promote exchanges and learning between basic scientists and clinical doctors in the fields of oncology and hematology, explore the application of the latest research achievements, address practical challenges in diagnosis and treatment, and drive the coordinated development of disciplinary progress and medical standards.

"Drug-Resistant Tuberculosis Diagnosis and Treatment Capacity Improvement Project"

Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis infection, also known as "phthisis," with a prolonged course that seriously affects patients' lives. China is a high-burden country for drug-resistant tuberculosis, with low patient detection rates, low treatment enrollment rates, and low treatment success rates, posing significant challenges to tuberculosis prevention and control efforts and national public health management in China. The "14th Five-Year Plan for National Health" explicitly states the need to establish a stable investment mechanism for public health services, strengthen talent development, improve basic disease control conditions, refine public health service programs, and reinforce grassroots public health systems. Based on the current status of tuberculosis prevention and control in China, Janssen China has partnered with the Chinese Anti-Tuberculosis Association to launch the "Drug-Resistant Tuberculosis Diagnosis and Treatment Capacity Enhancement Initiative." This project focuses on themes such as "detection and diagnosis," "standardized treatment," and "humanistic management" for the population affected by drug-resistant tuberculosis. By hosting expert high-level forums in the field of drug-resistant tuberculosis, it addresses the current state of drug-resistant tuberculosis prevention and control in China and closely explores standardized clinical diagnosis and treatment norms for drug-resistant tuberculosis in China over the next 3-5 years. It aims to support the realization of national tuberculosis prevention and control strategic goals and jointly promote the construction of China's public health service system.

Professor Cheng Shiming, Vice Chairman and Secretary-General of the Chinese Anti-Tuberculosis Association, stated, "Exploring the depth and breadth of patient services" requires the collaboration of multiple forces to promote the establishment of industry-related standards, thereby benefiting patients. The Anti-Tuberculosis Association will join hands with Janssen China to mobilize societal forces, bring together experts and scholars for academic discussions, participate in the establishment and implementation of relevant group standards, and promote the deep integration of industry, academia, research, and application. This will provide more scientific, full-process disease management services for drug-resistant tuberculosis patients.

Create New Records Together, a Promising Future for the "Deep Realm Initiative"

Xian Janssen in China Invited Nearly 3,000 Participants from Eight Cities to Wear Virtual Reality (VR) Glasses Both Online and Offline to Watch the VR Short Film *Deep Realm Project: Light*, Celebrating the Official Launch of Xian Janssen in China’s "2023 Deep Realm Project". The VR short film, in the form of human-computer interaction, illustrates Xian Janssen's transformative healthcare innovation journey — the endless scientific exploration and patient services are boundless life missions, akin to the mysterious uncharted deep realms of the universe, without boundaries, full of unknowns, and waiting to be explored and conquered by humanity.
With the release and launch of the "2023 Xian Janssen China Deep Realm Plan," Xian Janssen China solemnly commits to upholding the value principles of science-driven, mission-focused, and patient-first. It will deepen advancements in medical science, empower academic progress, and foster collaboration by establishing academic and strategic partnerships that engage all key stakeholders in the healthcare industry. Together, they will promote progress and development in disease areas and improve the healthcare ecosystem. By connecting doctors, patients, industry organizations, and other key parties, they will jointly address the various challenges currently impacting healthcare services in China through deep cooperation to advance the Healthy China initiative. At the same time, they will deeply understand patient needs and work with multiple parties to explore more "profound" and "extensive" patient service realms, challenging the boundaries of patient care.